Clinical stage biotechnology company ValiRx has completed data collection from a recent Phase II trial on its lung cancer treatment and is now taking steps towards completing a clinical study report for submission.
(WebFG News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the European Union patent and trademark office has granted EU Patent Application 08717866.1 - Anti-Androgen Peptides and Uses Thereof in Cancer Therapy - covering its lead therapeutic compound, VAL201, which was in clinical trials.
Clinical stage biotechnology company ValiRx has seen positive results from recent studies into the effectiveness of its VAL101 compound's ability to induce cancer cells to kill themselves off.
AIM-quoted life science company ValiRx narrowed losses in its most recent trading year after making "important strides" in growing its internal research and development capabilities.
Clinical stage biotechnology company ValiRx announced on Tuesday that the US patent and trademark office has granted the patent application 14/575065 (Anti-Androgen Peptides and Uses Thereof in Cancer Therapy), covering ValiRx's lead therapeutic compound, VAL201, which is in clinical trials.
Biopharmaceutical company ValiRX was said to be entering a "new and exciting phase" after it was granted approval to expand and accelerate its early-stage cancer study.
Cancer therapeutics and diagnostics-focussed life sciences company ValiRx issued its final results for the year to 31 December 2016 on Friday, with its losses widening as it ramped up testing and trials of its products in development.
Shares in ValiRx are up more than 6% after it said ValiSeek has made several significant steps of progression within the trial for the novel cancer-treatment drug VAL401.
Clinical stage biotechnology company ValiRx announced a placing to raise £1.16m on Wednesday.
Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reduction in PSA progression in the majority of patients.
Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401.
Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year.
ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients.
ValiRx was confident in the potential of two of its compounds on Tuesday, in its quarterly update on its ongoing clinical trials.
Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments.
ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy.
ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline.